Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928803 | 0.92 | CTSK (0.56) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL17108791 | 0.91 | CTSK (0.51) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL13255982 | 0.88 | CTSK (0.54) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL30371406 | 0.86 | KCNA3 (0.60) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL31460583 | 0.84 | CTSK (0.50) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL14737824 | 0.83 | CA1 (0.55) | CTSKKCNA3DRD2BTKCA1 | |
| SCHEMBL4623791 | 0.83 | EPHX1 (0.48) | CTSKKCNA3HPGDSDRD2EPHX1 | |
| SCHEMBL2379374 | 0.83 | CA1 (0.55) | CTSKKCNA3DRD2BTKCA1 | |
| SCHEMBL3965693 | 0.83 | CTSK (0.55) | CTSKKCNA3DRD2BTKCCR5 | |
| SCHEMBL27460572 | 0.83 | CTSK (0.55) | CTSKKCNA3DRD2BTKCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022048631-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-3390384-B1 | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2021-09-15 | — | — | EP | disclosed |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| CN-108430992-A | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | 阿斯特克斯医疗公司 | 2018-08-21 | — | — | CN | disclosed |
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-1228070-B1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2007-02-07 | — | — | EP | disclosed |
| US-6861423-B2 | Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds | SYNTEX (U.S.A.) LLC (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | SYNTEX (U.S.A) LLC | 2003-08-14 | — | — | US | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
| US-6451804-B1 | Heteroalkylamino-substituted bicyclic nitrogen heterocycles | SYNTEX (U.S.A.) LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1228070-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | CTSK 3215/4885KCNA3 3775/4885HPGDS 1/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | CTSK 3215/4885KCNA3 3775/4885HPGDS 1/4885 |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | CTSK 2445/4885KCNA3 3649/4885HPGDS 2383/4885 |
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | CTSK 4219/4885KCNA3 4533/4885HPGDS 3420/4885 |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | AR, PARP1, DPYD | CTSK 4162/4885KCNA3 1186/4885HPGDS 3474/4885 |
| US-20210238162-A1 | CHEMICAL COMPOUNDS | HPGDS, PTGS1, PTGIS | CTSK 2764/4885KCNA3 2805/4885HPGDS 1/4885 |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | CTSK 2911/4885KCNA3 2185/4885HPGDS 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.